Peter P. De Deyn
Advanced in Developmental Dysphasia Familial

Peter P. De Deyn

Antwerpen, VLG, BE 
Advanced in Developmental Dysphasia Familial
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Peter De Deyn practices in Antwerpen, Belgium. Mr. De Deyn is rated as an Advanced expert by MediFind in the treatment of Developmental Dysphasia Familial. His top areas of expertise are Dementia, Alzheimer's Disease, Frontotemporal Dementia, and Vascular Dementia.

His clinical research consists of co-authoring 376 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Developmental Dysphasia Familial.

Gender
Male

Locations

Antwerpen, VLG 2610, Belgium
Other Locations
Wilrijk, VLG 2610, Belgium
Born, WAL, Belgium
Edegem, VLG, Belgium
Route De Lennik, No 808, Brussels, BRU 1070, Belgium
Gent, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug, Other
Study Drug: IONIS MAPTRx
Study Phase: Phase 1
View 1 Less Clinical Trial

374 Total Publications

Dementia risk prediction in the general population: external validation of a prediction model in the population-based LifeLines Cohort Study.
Dementia risk prediction in the general population: external validation of a prediction model in the population-based LifeLines Cohort Study.
Journal: JAR life
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Deyn's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile